Ontology highlight
ABSTRACT: Background
Neratinib is in Phase 3 clinical trials but, unfortunately, the development of resistance is inevitable. Here, we investigated the effects of acquired neratinib resistance on cellular phenotype and the potential mechanism of this resistance.Methods
Neratinib-resistant variants of HER2-positive breast cancer cells were developed and their cross-resistance investigated using cytotoxicity assays. Similarly, sensitivity of trastuzumab-resistant and lapatinib-resistant cells to neratinib was assessed. Cellular phenotype changes were evaluated using migration, invasion and anoikis assays. Immunoblotting for HER family members and drug efflux pumps, as well as enzyme activity assays were performed.Results
Neratinib resistance conferred cross-resistance to trastu
SUBMITTER: Breslin S
PROVIDER: S-EPMC5344284 | biostudies-literature | 2017 Feb
REPOSITORIES: biostudies-literature